



Benign prostate enlargement: Drug use increases exponentially

The National Board of Health and Welfare's newly published statistics show that 215,800 Swedish men collected "Medicines for benign prostate enlargement" against prescriptions in pharmacies in 2021. This is 137% more than 15 years ago.

The State's Preparation for Medical and Social Evaluation (SBU) has previously concluded that moderate symptoms of benign prostate enlargement are often treated with medicines, but since it is not possible to in advance determine which men will benefit from the treatment, it is important that the prescribing doctor follows up on the effect. For those who have severe problems, there are several effective surgical methods. But the quality of life is decreasing in many who do not get help. The evaluation shows that drugs generally have a modest effect on moderate prostate problems, although some men benefit from them. However, these cannot be identified in advance, which is why it is of great importance to monitor the effects of started medication carefully and systematically.

Sonny Schelin, Doctor of Urology and Specialist in General Surgery, pointed out a couple of years ago about the worrying trend: *"Many doctors in Sweden choose to prescribe symptom-relieving drugs to patients instead of offering a curative treatment. Drug treatment can cause troublesome side effects such as fatigue, dizziness, dry mouth, decreased sex drive and impotence. I can't understand why many doctors do this when we can offer the patient an effective treatment. It is both difficult and unnecessary to suffer when there is help available. Waiting and walking with an enlarged bladder impairs the chances of cure if you wait too long so the bladder loses elasticity."*

Although the number of thermotherapy treatments with CoreTherm has increased sharply in recent years, there has been a dramatic decrease in the number of curative treatments for benign prostate enlargement in Sweden over the past 25 years, even though the older male population has increased rapidly during the same time.

ProstaLund's CEO, Johan Wennerholm comments: "The knowledge that there are more and more men who are getting nothing but alfuzosin and finasteride to relieve their symptoms while fewer and fewer are receiving curative treatment makes me sad. At the same time, these figures show that the potential for CoreTherm, only in Sweden, is huge and it is a great incentive for us to continue our insistent work to enlighten all these gentlemen about thermotherapy treatment and to try help them to cure."

See attached image for complete graph.

PRESS RELEASE
04 March 2022 15:00:00 CET



For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented ThermoTherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Image Attachments

Läkemedel 2021 215800 EN

Attachments

Benign prostate enlargement: Drug use increases exponentially